TENVIR EM inhibits reverse transcriptase, a key enzyme required for HIV replication. The emtricitabine–tenofovir combination reduces viral load and helps maintain immune system stability.
Recommended for:
Individuals diagnosed with HIV infection
People at high risk of HIV exposure (as PrEP)
Use in combination antiretroviral therapy (ART)
Serodiscordant couples (one partner HIV-positive, one negative)
HIV-1 treatment in adults and adolescents
Pre-exposure prophylaxis (PrEP) for HIV-negative individuals at risk
Taken orally once daily, with or without food, as part of ART or PrEP, according to a healthcare provider’s instructions.
Contraindications:
Hypersensitivity to any component
Severe renal impairment
Use in children without medical supervision
Side Effects:
Nausea, diarrhoea
Insomnia
Fatigue
Decreased bone mineral density (long-term use)
Renal function impairment
